In HNSCC xenograft models, treatment with a novel anti-FAP monoclonal antibody-maytansinoid conjugate (FAP5-DM1) resulted in sustained suppression of tumour progression with excellent efficacy and tolerability. This evidence concerns the gene FAP and head and neck squamous cell carcinoma.